Document 2819
 DOCN  M94A2819
 TI    CD4 cell count in HIV-infected patients treated with oral IFN
       alpha--preliminary report.
 DT    9412
 AU    Smiatacz T; Dzierbicki A; Trocha H; Zielinska W; DPT, Gdansk School of
       Medicine, Poland.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):218 (abstract no. PB0303). Unique
       Identifier : AIDSLINE ICA10/94369756
 AB    OBJECTIVE: Evaluation of the influence of oral IFN (interferon) alpha
       monotherapy of HIV-infected patients on the CD4 and CD8 cell count in
       peripheral blood. METHODS: We studied 22 HIV-infected patients with
       initial CD4 cell count less than 500 per cu mm during a period of 90
       days. 11 of them received oral IFN alpha, 100u daily. 3 of them were
       treated with AZT (zidovudine), 600-1200 mg per day. The remaining 8
       patients did not receive any treatment because of lack of compliance
       (active drug users). CD4 and CD8 cell count were determined using
       fluorochrome labeled monoclonal antibodies (Becton-Dickinson) and
       FACSort flow cytometer. TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSIONS:
       After 90 days of treatment there was no significant difference in CD4
       and CD8 cell count alteration between these groups of patients. However
       an astounding improvement in general condition of the patients receiving
       oral IFN alpha was observed. A follow-up study is essential to evaluate
       the relevance of the results obtained.
 DE    Biological Response Modifiers/*PHARMACOLOGY/THERAPEUTIC USE  Combined
       Modality Therapy  CD4-CD8 Ratio/DRUG EFFECTS  Human  HIV
       Infections/BLOOD/DRUG THERAPY/*THERAPY
       Interferon-alpha/*PHARMACOLOGY/THERAPEUTIC USE  Leukocyte Count/*DRUG
       EFFECTS  T-Lymphocytes, Suppressor-Effector  Treatment Outcome  *T4
       Lymphocytes  Zidovudine/THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).